Patents by Inventor Leo Thomas

Leo Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20250051460
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: August 19, 2024
    Publication date: February 13, 2025
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • AUDIO DATA SHARING METHOD FOR RADIO BROADCASTING
    Publication number: 20240348357
    Abstract: An audio data sharing method for radio broadcast systems includes sharing audio data using vehicle-to-vehicle communication and vehicle-to-infrastructure communication between vehicles and infrastructure units in low reception areas for radio broadcasting. The audio data sharing occurs by means of tuner leasing. The method also includes forming a framework for message sharing between the different units. The method enables uninterrupted audio data availability in low reception areas for enhancing the customer experience.
    Type: Application
    Filed: August 2, 2023
    Publication date: October 17, 2024
    Applicant: INNTOT TECHNOLOGIES PRIVATE LIMITED
    Inventors: GEETHU STANLY, ASWIN KARAYEE, SAHIRA ENCHAKKUDY KUNJUMUHAMMED, LEO THOMAS, NIKHIL CHERIAN
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 12115179
    Abstract: The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: October 15, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, Rolf Grempler
  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20240336674
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: January 26, 2024
    Publication date: October 10, 2024
    Inventors: Leo THOMAS, Rachel Rebecca BARRETT, Kristin Laura BOVAT, Rajkumar GANESAN, Priyanka GUPTA, Fei HAN, Dongmei LIU, Juergen PRESTLE, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Helen Haixia WU, Nina ZIPPEL
  • Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases
    Patent number: 12110335
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 8, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Michael Benz, Remko Alexander Bakker, Holger Fuchs, Fei Han, Sandeep Kumar, Sarah Low, Justin M. Scheer, Leo Thomas
  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING A THROMBOTIC DISEASE OF THE RETINA
    Publication number: 20240228600
    Abstract: The invention relates to the use of antibodies and antibody that target semaphorin 3A (Sema3A), and fragments thereof, and their use for treating thrombotic diseases of the retina comprising.
    Type: Application
    Filed: December 8, 2023
    Publication date: July 11, 2024
    Inventors: Leo THOMAS, Remko Alexander BAKKER
  • GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
    Publication number: 20240123037
    Abstract: The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Inventor: Leo THOMAS
  • ANTI-NRP1A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20230416378
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Application
    Filed: April 7, 2023
    Publication date: December 28, 2023
    Inventors: Nina ZIPPEL, Pankaj GUPTA, Fei HAN, Yining HUANG, Sarah LOW, Juergen PRESTLE, Leo THOMAS
  • Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
    Patent number: 11813312
    Abstract: The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Leo Thomas
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20230355638
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: July 14, 2023
    Publication date: November 9, 2023
    Inventors: Matthias ECKHARDT, Marina Kristina WILLWACHER, Juergen PRESTLE, Ferenc KONTES, Leo THOMAS, Christofer Siegfried TAUTERMANN, Dieter WIEDENMAYER
  • Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
    Patent number: 11766443
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Marina Kristina Willwacher, Juergen Prestle, Ferenc Kontes, Leo Thomas, Christofer Siegfried Tautermann, Dieter Wiedenmayer
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20230285432
    Abstract: The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 14, 2023
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • Anti-NRP1A antibodies and their uses for treating eye or ocular diseases
    Patent number: 11661458
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Nina Zippel, Pankaj Gupta, Fei Han, Sarah Low, Juergen Prestle, Leo Thomas
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220313716
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: June 3, 2022
    Publication date: October 6, 2022
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20220160725
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 26, 2022
    Inventors: Matthias ECKHARDT, Marina Kristina WILLWACHER, Juergen PRESTLE, Ferenc KONTES, Leo THOMAS, Christofer Siegfried TAUTERMANN, Dieter WIEDENMAYER
  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20220144929
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Inventors: Leo THOMAS, Rachel Rebecca BARRETT, Kristin Laura BOVAT, Rajkumar GANESAN, Priyanka GUPTA, Fei HAN, Dongmei LIU, Juergen PRESTLE, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Helen HAIXIA WU, Nina ZIPPEL
  • ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING A THROMBOTIC DISEASE OF THE RETINA
    Publication number: 20220127344
    Abstract: The invention relates to the use of antibodies and antibody that target semaphorin 3A (Sema3A), and fragments thereof, and their use for treating thrombotic diseases of the retina comprising.
    Type: Application
    Filed: October 21, 2021
    Publication date: April 28, 2022
    Inventors: Leo THOMAS, Remko Alexander BAKKER
  • AGONISTIC TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119536
    Abstract: The invention relates to agonistic TrkB binding molecules, methods for improving agonistic TrkB binders, their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119535
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • Acylated glucagon analogue
    Patent number: 11274136
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: March 15, 2022
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas